YYYong Yang

Yong Yang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yong Yang has a total of 37 co-authors. Here are the top co-authors by number of shared publications:

  • Can Li

    Department of Urology, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Peking University Cancer Hospital Yunnan

    2 shared publications
  • Chengwei Bi

    Department of Urology, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University, Peking University Cancer Hospital Yunnan, Kunming, China

    2 shared publications
  • Hanbin Li

    Department of Urology, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Peking University Cancer Hospital Yunnan

    2 shared publications
  • Libo Yang

    Department of Urology, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Peking University Cancer Hospital Yunnan

    2 shared publications
  • SiNan Yang

    Department of Urology, Yunnan Cancer Hospital, Third Affiliated Hospital of Kunming Medical University, Peking University Cancer Hospital Yunnan, Kunming, China

    2 shared publications
  • Sinan Yang

    Department of Urology, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Peking University Cancer Hospital Yunnan

    2 shared publications

Latest Publications

  • Open Access

    Case report and literature review: key clinical management points and prognostic analysis of paraganglioma of the urinary bladder

    by Chengbin Lu, Benmo Xu, Can Li, Sinan Yang, Xusong Pang, Weixiang Yang, Tianjian Xie, Zongyan Luo, Hanbin Li, Wei Luo, et al.

    Objective: To investigate the clinical characteristics, diagnostic approach, perioperative management, and key considerations in surgical decision-making for functional bladder paraganglioma. Methods: We conducted a retrospective analysis of the clinical data of a patient with pathologically confirmed bladder paraganglioma and discussed the findings in the context of relevant domestic and international literature. Results: The patient was a 50-year-old man who presented with frequent urination, urinary urgency, and dysuria for more than 2 months, accompanied by paroxysmal hypertension during urination with a peak blood pressure of 205/120 mmHg. Diagnostic transurethral resection of the bladder tumor was performed at another hospital, and postoperative pathology indicated paraganglioma. Upon admission to our hospital, further testing revealed markedly elevated plasma levels of norepinephrine and methoxy norepinephrine. Contrast-enhanced pelvic MRI revealed a mass on the right bladder wall involving the right ureteral orifice, accompanied by right-sided hydronephrosis and suspicious pelvic lymph nodes. After multidisciplinary discussion and thorough preoperative preparation including α-receptor blockade and volume expansion, the patient underwent radical cystectomy with bilateral pelvic lymphadenectomy and ileal neobladder reconstruction. Postoperative pathology confirmed bladder paraganglioma invading the full thickness of the bladder detrusor muscle (deep muscular layer) with a Ki-67 index of approximately 8%, and no lymph node metastasis was observed in 18 examined lymph nodes (7 left pelvic and 11 right pelvic). During the 5-month postoperative follow-up, no obvious recurrence or metastasis was detected. Conclusion: Urination-related paroxysmal hypertension is the pathognomonic sign of functional bladder paraganglioma. Preoperative catecholamine metabolite testing combined with pelvic contrast-enhanced MRI forms the core diagnostic system. Multidisciplinary collaboration-based perioperative management and individualized surgical resection are the keys to improving prognosis, and lifelong follow-up is mandatory for all patients.

  • Open Access

    Pembrolizumab induced life threatening adrenal crisis in a patient with recurrent adrenocortical carcinoma after unilateral adrenalectomy

    by Benmo Xu, Chengbin Lu, Sinan Yang, Weixiang Yang, Hanbin Li, Guomin Tian, Yingling Du, Jiasheng Wu, Duoneng Zhang, Wei Luo, et al.

    A 58-year-old female patient with recurrent left adrenal cortical carcinoma following surgery developed severe nausea, vomiting, anorexia, and hypovolemic shock, accompanied by profound hyponatremia, approximately 2 weeks after receiving pembrolizumab immunotherapy. She was diagnosed with an acute adrenal crisis. The patient had a prior history of mitotane therapy and radiotherapy. It was believed that the adrenal crisis was triggered by pembrolizumab-induced immune-mediated adrenalitis, compounded by cumulative damage to adrenal function from both the treatment and the tumor. After aggressive management, including anti-shock treatment, high-dose glucocorticoid replacement, and symptomatic supportive care, the patient's condition improved. At the 1-month follow-up after discharge, the patient had fully recovered, with normalized hormone levels and no evidence of tumor progression. This case highlights the potential for immune checkpoint inhibitor therapy to induce life-threatening adrenal crises in patients with pre-existing adrenal insufficiency. Clinicians must remain highly vigilant, performing early hormone level screening, promptly initiating hormone replacement therapy, and ensuring multidisciplinary team (MDT) collaboration to improve patient outcomes.


  • Open Access

    Case Report: Surgical androgen deprivation therapy for prostate cancer in a patient with concurrent scrotal paget’s disease

    by Sinan Yang, Qiao Wang, Yuanlong Shi, Bo Peng, Jinye Yang, Zongyan Luo, Can Li, Jian Xu, Wei Luo, Chengwei Bi, et al.

    Introduction: Prostate cancer (PCa) and Scrotal Paget’s disease (SPD) are two distinct malignancies, and reports of their concurrent occurrence are very limited. The aim of this case was to discuss the individualized treatment strategy for an elderly patient with metastatic PCa combined with SPD.Case presentation: An octogenarian male (aged 88 years) with metastatic PCa (Gleason 8 = 4 + 4, bone metastases, suspected lung involvement) received androgen deprivation therapy (ADT: bicalutamide + goserelin), achieving biochemical control (PSA <0.1 ng/mL; testosterone <20 ng/dL) over three years (2020-2023). In September 2023, he developed a painless scrotal nodule (0.5 cm), which progressed to a 3 cm ulcerated lesion with pruritus and bleeding by December 2023. Histopathology confirmed SPD. After multidisciplinary review and family prioritization of symptom relief, wide local excision (3-cm margins) and bilateral orchiectomy were performed on December 9, 2023. Postoperative pathology confirmed a primary SPD (CK7+/GCDFP-15+). Postoperative recovery was uncomplicated, and no recurrence was observed at the one-year follow-up in December 2024.Clinical discussion: Dual pathology requires a multimodal approach. Surgery can control symptoms, simplify ADT, and reduce the risk of SPD recurrence. This decision requires balancing tumor efficacy, age, and quality of life (QoL).Conclusion: Combined surgical resection and ADT may benefit older patients with synchronous PCa and SPD(CK7+/GCDFP-15+), but patient selection and informed consent remain critical.

  • Open Access

    A Novel Prognostic Model Based on Ferroptosis-Related Gene Signature for Bladder Cancer

    by Libo Yang, Chunyan Li, Yang Qin, Guoying Zhang, Bin Zhao, Ziyuan Wang, Youguang Huang, Yong Yang

    Background: Bladder cancer (BC) is a molecular heterogeneous malignant tumor; the treatment strategies for advanced-stage patients were limited. Therefore, it is vital for improving the clinical outcome of BC patients to identify key biomarkers affecting prognosis. Ferroptosis is a newly discovered programmed cell death and plays a crucial role in the occurrence and progression of tumors. Ferroptosis-related genes (FRGs) can be promising candidate biomarkers in BC. The objective of our study was to construct a prognostic model to improve the prognosis prediction of BC.Methods: The mRNA expression profiles and corresponding clinical data of bladder urothelial carcinoma (BLCA) patients were downloaded from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases. FRGs were identified by downloading data from FerrDb. Differential analysis was performed to identify differentially expressed genes (DEGs) related to ferroptosis. Univariate and multivariate Cox regression analyses were conducted to establish a prognostic model in the TCGA cohort. BLCA patients from the GEO cohort were used for validation. Gene ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), and single-sample gene set enrichment analysis (ssGSEA) were used to explore underlying mechanisms.Results: Nine genes (ALB, BID, FADS2, FANCD2, IFNG, MIOX, PLIN4, SCD, and SLC2A3) were identified to construct a prognostic model. Patients were classified into high-risk and low-risk groups according to the signature-based risk score. Receiver operating characteristic (ROC) and Kaplan–Meier (K–M) survival analysis confirmed the superior predictive performance of the novel survival model based on the nine-FRG signature. Multivariate Cox regression analyses showed that risk score was an independent risk factor associated with overall survival (OS). GO and KEGG enrichment analysis indicated that apart from ferroptosis-related pathways, immune-related pathways were significantly enriched. ssGSEA analysis indicated that the immune status was different between the two risk groups.Conclusion: The results of our study indicated that a novel prognostic model based on the nine-FRG signature can be used for prognostic prediction in BC patients. FRGs are potential prognostic biomarkers and therapeutic targets.